Never before has the shifting US and European regulatory landscape demanded so much attention on safety and complex study data considerations affecting a product's commercial future. With the race to market heating up, many developers are short sighted, using partners for Phase I-III without considering the implications of late phase study demands. Engaging partners at the front end of a study should be considered a best practice to maximize product success in post market studies.

Download, "Early Planning Essential, Best Practices in late Phase Drug and Device Research," to understand how to avoid pitfalls in your race to commercial success.